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Summary 21 
Current guidelines advocate using fixed-doses of oral vitamin K to reverse excessive 22 
anticoagulation in warfarinised patients either asymptomatic or with minor bleeds. 23 
Over-anticoagulated patients present with a wide range of INR values and response to 24 
fixed doses of vitamin K varies. Consequently a significant proportion remain outside 25 
their target INR after vitamin K administration making them prone to either 26 
haemorrhage or thromboembolism. We compared the performance of a novel tailored 27 
vitamin K dosing regimen to that of a fixed-dose regimen with the primary measure 28 
being the proportion of over-anticoagulated patients returning to their target INR 24h 29 
later. 181 patients with an index INR >6.0 (asymptomatic or with minor bleeding) were 30 
randomly allocated to receive orally either a tailored dose (based upon index INR and 31 
BSA), or a fixed-dose (1 or 2mg) of vitamin K.  Compared to the fixed-dose regimen, the 32 
tailored dose resulted in a greater proportion of patients returning to within target INR 33 
range (68.9% v 52.8%; p=0.026), whilst a smaller proportion of patients remained 34 
above target INR range (12.2% v 34.0%; p<0.001).  Individualised vitamin K dosing is 35 
more accurate than fixed-dose regimen in lowering INR to within target range in 36 
excessively anticoagulated patients. 37 
 38 
No of words: 195 39 
 40 
 41 
Trial is registered with ISRCTN Registry; Clinical Trial Registration no- ISRCTN79841657; 42 
URL: http://www.isrctn.com/ 43 
 44 
Key words: Anticoagulation, warfarin, vitamin K, thrombosis, bleeding  45 
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Introduction 46 
Despite improvements in the management of warfarin therapy, 50% of patients fail to 47 
stabilise within their target INR range and are thus prone to the drug’s adverse effect of 48 
bleeding (Watson, et al 2001). Subgroup analyses of several studies show a sharp 49 
increase in the risk of bleeding when the INR exceeds the therapeutic range and 50 
increased risk of thrombosis when the INR falls below it (Fihn, et al 1996, No author 51 
1996a, No author 1996b). The annual frequency of major bleeding events associated 52 
with excessive anticoagulation with warfarin ranges from 2.0 to 3.5% (Lip, et al 2011, 53 
1994), with the absolute risk of thrombosis associated with overcorrection being in the 54 
same range (Hanslik and Prinseau 2004). 55 
 56 
The current guidelines for treating over-anticoagulated patients advocate restoration of 57 
the INR to the target range quickly in order to prevent bleeding whilst avoiding over-58 
correction which increases the patient’s risk of thromboembolism. Apart from warfarin 59 
discontinuation, non-urgent correction of over-anticoagulation is achieved through oral 60 
vitamin K administration (Makris and Watson 2001). Although oral vitamin K is 61 
effective in lowering INR in over-anticoagulated patients (Crowther, et al 2000, Watson, 62 
et al 2001) , the currently used fixed-dose regimens do not adequately allow for 63 
differences in individual patient INR values. Whilst in excessively anticoagulated 64 
patients a particular dose may fail to sufficiently lower the INR, it can lead to over-65 
correction in those who are only mildly over-anticoagulated (Denas, et al 2009, Sconce 66 
and Kamali 2006).  67 
 68 
In an earlier pilot study, we demonstrated that individualized vitamin K dosing, based 69 
upon index INR, resulted in a significantly greater proportion of over-anticoagulated 70 
Page 4 of 32 
 
patients having INR 1.8-4.0 at 24h compared to data held in clinic on patients receiving 71 
a fixed-dose regimen (71% v 39%; p<0.001) (Briz, et al 2010).  The data generated from 72 
this pilot study helped us to develop a new improved individualized vitamin K dosing 73 
algorithm, based upon index INR and body surface area (BSA), which was estimated to 74 
have a greater power of accuracy in computing vitamin K dose for lowering INR to 75 
within therapeutic target range in over-anticoagulated patients than the original dosing 76 
algorithm (Briz, et al 2010).  We assessed the performance of the improved ‘tailored’ 77 
vitamin K dosing regimen against a fixed-dose regimen currently used in our local 78 
hospitals in the reversal of warfarin-induced over-anticoagulation in a randomized 79 
controlled clinical trial. As part of the trial we also investigated retrospectively the 80 
potential impact of patient factors, as well as genetic factors which influence warfarin 81 
pharmacology and metabolism and vitamin K disposition, on the extent of INR reversal. 82 
 83 
Methods 84 
Patient Recruitment  85 
This single-centre, open-label, randomized controlled study had approval by the 86 
National Research Ethics Service-Committee North East, Newcastle & North Tyneside 87 
(ref: 11/NE/0249). The trial was registered with the ISRCTN Registry under the name 88 
‘Reversal of over-anticoagulation with vitamin K’ (trial registration no: 89 
ISRCTN79841657). Over-anticoagulated patients presenting to the anticoagulant clinics 90 
at the Royal Victoria Infirmary and the Freeman Hospital, Newcastle upon Tyne were 91 
recruited into the study.  Patients on warfarin therapy (irrespective of the duration) 92 
referred to our clinics with supra-therapeutic INR and either asymptomatic or with 93 
minor bleeds, according to the classification of Fihn et al (Fihn, et al 1996), were eligible 94 
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to take part. As in our earlier pilot study, only patients with a confirmed venous INR 95 
≥6.0 were eligible, based on evidence that such patients are at significant risk of 96 
imminent harm, with a recorded risk of 8.8% for abnormal bleeding and 4.4% for a 97 
major bleed in the following 14 days compared to no bleeds occurring in a control 98 
population within target INR range over the same period (Hylek, et al 2000). Patients 99 
were excluded if they met one or more of the following criteria: younger than 18 years 100 
of age, life expectancy less than 10 days, presence of major bleeding requiring 101 
immediate and complete correction of anticoagulation, a history of thromboembolic / 102 
major haemorrhagic event in the previous 3 months, known sensitivity to vitamin K, 103 
liver disease, indication for acute normalisation of INR (such as imminent surgery), 104 
scheduled discontinuation of warfarin therapy, receiving thrombolytic therapy within 105 
48 hours, a platelet count less than 50x109 cells/L, unable to return to the clinic the next 106 
day for laboratory/clinical assessment.  107 
 108 
Study protocol 109 
On presentation, after confirmation of eligibility and having obtained informed consent, 110 
5ml venous blood was taken from each patient and transferred into EDTA tubes for 111 
later DNA extraction and genotyping for the VKORC1, CYP2C9 and CYP4F2 genes. 112 
Information on patient age, sex, body weight, height, co-morbidities and concurrent 113 
therapy was collected. Possible reasons for over-anticoagulation were ascertained (e.g. 114 
increased alcohol consumption, change in medication and change in dietary habits).  115 
Patients were allocated using block randomisation (block size=10) to two groups 116 
(‘control’ and ‘tailored dose’) to receive oral vitamin K1 (phytomenadione; Konakion®, 117 
Roche). The control group received vitamin K1, either 1 or 2 mg p.o. based on index INR 118 
and bleeding risk according to the current guidelines in place in the Northern Region 119 
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Hospitals for reversal of non-urgent over-anticoagulation (Hanley 2004, Keeling, et al 120 
2011). The vitamin K1 dose for those patients who were randomised to the ‘tailored 121 
dose’ arm was calculated in the clinic using a simple calculator generated within a 122 
Microsoft® Excel file which employed the following formula: Vitamin K1 dose (mg) = 123 
(0.247 x index INR on entry- target INR -0.1320+1.417 x BSA (m2))/1.0135 (Briz, et al 124 
2010). This algorithm was developed by regressing the target INR to index INR, BSA and 125 
vitamin K dose received. Body surface area was calculated using the Du Bois formula as 126 
follows: BSA = [0.007184 x height (cm) 0.725 x weight (kg) 0.425] (Du Bois and Du Bois 127 
1916).  128 
 129 
A further venous sample for INR determination was taken at 24 (+/- 3) hours.  The INR 130 
check was performed by personnel unsighted to the study treatment, thus preserving 131 
the study blindness. The individual patient’s warfarin therapy was re-started 24 hours 132 
after vitamin K ingestion, as instructed by the responsible physician/pharmacist, based 133 
on the DAWN AC dosing program (Poller, et al 1998), providing that the patient was no 134 
longer over-anticoagulated.  135 
 136 
The need for additional doses of vitamin K at ≥24h was considered if the patient’s INR 137 
was >6.0 outside of the study following the local guidelines (Keeling, et al 2016). The 138 
need for low molecular weight heparin (LMWH) administration at ≥24h was considered 139 
if the patient’s INR was sub-therapeutic and he/she was clinically adjudged to be at high 140 
risk of thrombosis. The decision for bridging with LMWH in all patients with sub-141 
therapeutic INR results was made following an assessment of the patient’s thrombotic 142 
risk according to the following clinical scenarios: (a) history of previous VTE whilst INR 143 
Page 7 of 32 
 
was within therapeutic range with subsequent re-assignment to a higher target INR of 144 
3.5; (b) mechanical heart valve (other than a bileaflet aortic valve) (Keeling, et al 2016). 145 
LMWH administration was also considered if INR value was below the lower limit of the 146 
therapeutic range by ≥0.3 unit. 147 
 148 
Patients were followed-up at two further clinic visits (day 7 (+/-2 days) & day 14 (+/-2 149 
days)) to check for anticoagulation control and possible adverse effects of 150 
thromboembolism or haemorrhage using standard proforma of questions. Further 151 
observational information on thromboembolism/bleeding events was collected from 152 
patients’ notes up to 30 days after the administration of the first dose of vitamin K.  153 
 154 
The study protocol was amended later during the trial to make the visits on days 7 and 155 
14 optional for patients in an attempt to boost recruitment. The amendment also 156 
involved inclusion of patients with repeated admissions to clinic for excessive 157 
anticoagulation. We allowed for double inclusion of patients with supra-therapeutic INR 158 
provided that there was sufficient length of time (minimum 30 days) between each 159 
episode, which would not bias the conclusions of the study. 160 
 161 
Primary & Secondary outcome measures 162 
The primary measure was the proportion of patients reaching to within ±0.2 units of 163 
their absolute therapeutic INR range (reported as ‘within target range’) 24 hours after 164 
receiving oral vitamin K in the ‘tailored dose’ group compared to the ‘control’ group. An 165 
INR value of >0.2 units below or above the individual target INR range at 24 hours was 166 
considered as over- and under-correction of over-anticoagulation, respectively, as these 167 
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ranges (according to our local practice) are deemed to be clinically relevant thus 168 
prompting the personnel in charge of patient anticoagulation management to consider 169 
the possible need for intervention. 170 
 171 
Secondary measures included the need for repeated doses of vitamin K1, the need for 172 
heparin administration and the presence of any thromboembolic / haemorrhagic events 173 
during the study period. 174 
 175 
Genotyping 176 
Leukocyte DNA was extracted from blood samples according to an established in-house 177 
method (Daly, et al 1996). Genotyping for VKORC1 (-1639G>A; rs9923231), CYP2C9 (*2 178 
and *3 alleles; rs1799853 and rs1057910) and CYP4F2 (V433M; rs2108622) was 179 
performed using the StepOneTM Real-Time PCR System with Taqman® SNP Genotyping 180 
Assays, Applied BiosystemsTM.  Genotype results for all polymorphisms were validated 181 
using control samples that had been genotyped as part of a previous study (Biss, et al 182 
2012). 183 
 184 
Sample Size  185 
Based on our clinic data for a 12-month period, just over 30% of non-urgent cases over-186 
anticoagulated with warfarin achieved an INR within their target range 24 hours after 187 
oral vitamin K (1 or 2 mg p.o.) administration. To detect a 20% increase (i.e. from 30 to 188 
50%) in the proportion of over-anticoagulated patients achieving their target INR 24 189 
hours after vitamin K administration using the new tailored dosing regimen, with 80% 190 
power and at the 5% significance level, required 93 patients in each of the two study 191 
groups.  192 
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 193 
Statistical analysis 194 
Statistical analyses were performed using Minitab 17.0 (Coventry, UK). Data were 195 
checked for having a normal distribution. Where data were not normally distributed, 196 
logarithmic transformation was applied in order to achieve normality. Two sample t-tests 197 
were done if approximate normality was achieved. Otherwise, Mann-Whitney U-tests were 198 
used. Chi-squared tests were performed for comparing categorical data across groups. 199 
Pearson correlation test was used to evaluate relationships between variables. Stepwise 200 
regression analysis of data was used to evaluate the impact of patient characteristics 201 
and genetic polymorphism in VKORC1, CYP2C9 and CYP4F2 on INR reversal. Results are 202 
presented as mean ± SD (range) unless otherwise stated. A P value of < 0.05 was taken 203 
as statistically significant. 204 
 205 
Results 206 
Between June 2012 and February 2016, 186 patients (10 repeat cases) were recruited 207 
into the study. Five patients were later withdrawn; 3 due to administrative problems 208 
associated with screening, one lost to follow-up and one failed screening. Of the 209 
remaining 181 cases, 91 (including 2 repeat cases) were allocated to the control group 210 
and 90 (including 6 repeat cases) to the tailored dose group. 211 
 212 
The two groups were well matched with respect to demographic and clinical 213 
characteristics (Table I).  Index INR on presentation for the whole study population 214 
was 8.0 ± 2.0 (5.3-21.8). Patients included in the study had different target INR ranges 215 
based on the indication for which they were being treated with warfarin.  216 
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The possible reasons for excessive anticoagulation (if recorded) were extracted from 217 
the patients’ clinical records. These included change in diet (41 patients), excessive 218 
alcohol consumption (7 patients) and change in medication (41 patients). Of the latter 219 
group of patients 12 had stopped taking a medication and 29 had started a new 220 
medication shortly prior to the event. Of the 12 patients, the medication was identified 221 
as having either major (in 6 patients), moderate (in 4 patients) or minor (in 2 patients) 222 
interaction with warfarin. Of the 29 patients the medication was identified as having 223 
either major (in 6 patients), moderate (in 9 patients) or minor (in 2 patients) 224 
interaction with warfarin; in the remaining 12 patients the medication was not deemed 225 
to interact with warfarin  226 
 227 
In the control group, 81 patients received 1mg of vitamin K and 9 patients received 2mg 228 
of vitamin K, while for 1 patient the vitamin K dose administered was not recorded. The 229 
tailored dose group on average received a higher dose of vitamin K than the control 230 
group (1.1±0.3, (1.0-2.0) vs 1.8±0.8 (0.4-6.0), 95% CI for difference: -0.8783, -0.5217; t-231 
test) (Figure 1). Male patients required greater doses of vitamin K than their female 232 
counterparts (95% CI for difference: 0.299-0.933; t-test) (Figure 2).   233 
 234 
Primary outcome 235 
Mean INR at 24 hours was different between the two study groups (95% CI of means: 236 
(0.1167- 0.3441; t-test) (Table II)). Overall, the tailored dose vitamin K regimen 237 
performed better than the fixed-dose regimen, in terms of the proportion of cases being 238 
within, above or below the target INR range at 24h (p=0.002; chi-squared test) (Table 239 
III).  240 
 241 
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A greater proportion of cases in the tailored dose group returned to within their 242 
individual target anticoagulation 24h after vitamin K dosing than the control group 243 
(68.9% v 52.8%, p=0.026; chi-squared test) (Table III). INR value at 24h was above 244 
target therapeutic range in a greater proportion of cases in the control group compared 245 
to those in the tailored dose group (34.0% v 12.2%, p<0.001; chi-squared test). The 246 
proportion of cases with over-corrected INR was not different between the tailored 247 
dose group (18.9%) and the fixed-dose group (13.2%) (Table III). The median (range) 248 
INR at 24h for the under- and over-corrected cases did not differ between the fixed-249 
dose and tailored dose regimens (for undercorrected cases 1.7 (1.2-2.6) vs 1.7 (1.1-2.6), 250 
for overcorrected cases 4.5 (3.3-16.3) vs 4.1 (3.3-5.4); Mann-Whitney test). 251 
 252 
Secondary outcomes 253 
For a subset of cases, INR values on day 7 (71 tailored dose and 77 fixed-dose) and day 254 
14 (63 tailored dose and 72 fixed-dose) following vitamin K administration were 255 
available. There was no difference in mean INR between both groups at either time-256 
point (54.5% v 53.5% for day 7; 58.3% v 52.4% for day 14) (Table III).  257 
 258 
Four cases in the control group had an INR >6.0 at 24h and subsequently received an 259 
oral dose of vitamin K, according to the study protocol. Of the 4 cases, 2 received a 260 
second additional dose of vitamin K 24 and 96 hours later. One case in the tailored dose 261 
group admitted with a urinary tract infection and raised INR of 7.5 received a second 262 
dose of vitamin K at 48h, following a rise in INR from 5.4 at 24 hours to 6.9 at 48 hours. 263 
On day 7, two cases in the control and two in the tailored group had an INR>6.0 and 264 
thus received a dose of vitamin K. Similarly, on day 14, three cases in the control and 265 
two in the tailored group received a dose of vitamin K. According to the study protocol, 266 
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the remaining cases with INR <6.0 at 24h were deemed not to require additional dose of 267 
vitamin K. One case with INR=6.7 at 24h was not deemed by the reviewing clinician to 268 
be at high risk of bleeding and hence did not receive an additional dose of vitamin K. 269 
 270 
Twenty nine cases (12 in the control and 17 in the tailored group) had a sub-therapeutic 271 
INR (where the INR value was below the lower limit of the therapeutic range by ≥0.3 272 
unit) at 24 hours. Of these LMWH was administered to only two subjects (one in each of 273 
the fixed-dose and tailored vitamin K dose group); both were on warfarin therapy for 274 
antiphospholipid syndrome and were deemed to be at increased risk of thrombosis. 275 
Twenty cases were administered heparin between 48 hours and 16 days after vitamin K 276 
administration. However, the decision to administer heparin to these subjects was not 277 
study-related and reflected alteration of anticoagulation during admission with the use 278 
of therapeutic or prophylactic LMWH while warfarin was interrupted (Table IV). 279 
 280 
Vitamin K has a short half-life of 1.5 to 3 hours, with main effect on anticoagulation 281 
appearing within 12-24 hours after its administration (Chibisov 2007). Therefore, 282 
events reported during the first 24-48 h after vitamin K administration, were 283 
considered as being related to study intervention (i.e. either vitamin K dose was 284 
insufficient to return INR to within target range or it was in excess of that required 285 
leading to over-correction of INR). No major bleeding events according to the ISTH 286 
classification (Schulman and Kearon 2005) were reported in the trial. Of the 10 minor 287 
bleeding adverse events recorded during the trial, 4 belonged to the control group and 6 288 
to the tailored dose group (Table V). Three of the bleeding episodes (1 in control group 289 
and 2 in tailored dose group) were reported within 2 to 7 days after the initial vitamin K 290 
dose administration. The remaining 7 minor bleeding events took place within 7 to 23 291 
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days following vitamin K administration (3 in control group and 4 in tailored dose 292 
group). All these events are in accordance with bleeding symptoms anticipated while on 293 
anticoagulation and were unrelated to the initial vitamin K dose administration. In all, 1 294 
thromboembolic event in the tailored vitamin K dose group was reported 4 days after 295 
the study intervention. The recurrence of thrombosis was associated with malignancy, 296 
with the patient’s INR in the therapeutic range and was therefore unrelated to vitamin K 297 
administration (Table V). 298 
 299 
Associations between genotype, patient characteristics and vitamin K dose 300 
No differences in genotype frequency for the VKORC1 (-1639G>A; rs9923231), CYP2C9 301 
(*2 and *3; rs1799853 and rs1057910) and CYP4F2 (V433M; rs2108622) genes were 302 
observed between the two study groups.  303 
 304 
According to stepwise regression analysis neither age, height, nor CYP2C9, VKORC1 and 305 
CYP4F2 genotype influenced INR at 24h. Index INR and vitamin K dose contributed to 306 
INR at 24h (R2=24.6%; p<0.001). Patient weight appeared to be a more significant 307 
predictor of INR at 24h compared to BSA, with the latter used in the tailored dosing 308 
algorithm to calculate vitamin K dose. In contrast to the fixed-dose the tailored vitamin 309 
K dose was influenced by both index INR and BSA as expected (Figure 3).  310 
 311 
The vitamin K dose for the control group was estimated using the tailored dose 312 
equation.  According to regression analysis the difference in vitamin K dose (predicted - 313 
actual dose) was associated with BSA (R2=32.7%; p<0.001) and index INR (R2=17.8%; 314 
p<0.001). The predicted dose of vitamin K increased with increasing BSA and index INR 315 
(Figure 4). The predicted vitamin K dose was higher than the actual dose administered 316 
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[1.7 (0.1 – 3.0) v 1.1 (1.0 – 2.0) mg; difference in dose: 0.6 (-1.0 – 2.0) mg]. For patients 317 
who had received the 1mg vitamin K dose (n=77) the predicted vitamin K dose was 318 
higher [1.7 (0.1 – 3.0) mg; mean difference: 0.7 (-0.9 – 2.0) mg], whilst for those who 319 
had received the 2mg dose (n=8) the predicted dose was slightly lower than the actual 320 
administered dose [1.9 (1.0 – 2.7); mean difference: -0.1 (-1.0 – 0.7) mg].  321 
 322 
The study results were used to produce a new and more refined vitamin K dosing 323 
algorithm. By regressing the target INR to index INR, vitamin K dose and weight, the 324 
following vitamin K dosing equation was produced:  325 
Vitamin K Dose = (0.4765 x index INR – target INR + 0.02109 x Weight – 0.645)/1.278; 326 
where: vitamin K dose is in milligrams and weight in kilograms. This formula predicts 327 
on average the same vitamin K dose for the group of patients with restored INR to 328 
within target range at 24 hours (mean dose change ±SD, 0.06±0.49; range, -1.19 to 329 
+1.53 mg). However, for the overcorrected group a reduced dose is predicted (mean 330 
dose change ±SD, 0.73±0.80; range, -1.04 to +2.18 mg), while for the under-corrected 331 
group a small increase in predicted dose is estimated (mean dose change ±SD, -332 
0.07±0.49; range, -0.91 to +0.95 mg). 333 
 334 
Discussion 335 
Bleeding is one of the most serious complications associated with warfarin therapy 336 
(Palareti, et al 1996). The risk of bleeding increases with excessive anticoagulation 337 
which occurs in approximately 0.2-0.3% of outpatients receiving long-term warfarin 338 
therapy per annum(Penning-van Beest, et al 2001).  339 
 340 
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Restoration of the INR towards the target therapeutic range in over-anticoagulated 341 
patients is the logical approach, with the choice of treatment depending upon the 342 
severity of patient symptoms and the anticipated risks.  Evidence from randomized 343 
controlled trials supports the use of oral vitamin K in lowering the INR in asymptomatic 344 
or mildly bleeding patients (Ageno, et al 2005, Crowther, et al 2000, Dezee, et al 2006, 345 
Lubetsky, et al 2003). However, there is no clear consensus about the optimal dose that 346 
should be given to patients. The majority of the reported studies have used fixed oral 347 
doses of vitamin K (ranging from 1.0 to 5.0 mg), based upon assigning dose according to 348 
a dichotomy of elevated INR values to reverse excessive anticoagulation, with a high 349 
percentage of patients at 24 hours after vitamin K dosing being either under- or over- 350 
anticoagulated, leaving them at risk of either thromboembolism or haemorrhage, 351 
respectively (Denas, et al 2009, Sconce and Kamali 2006). Current guidelines in our 352 
locality recommend intervention with 1 or 2mg vitamin K orally to accelerate INR 353 
lowering in patients presenting with an INR >8.0 and those with INR of 4.5-7.9 deemed 354 
at high risk of bleeding (Hanley 2004, Keeling, et al 2011).   355 
 356 
A tailored approach to vitamin K dosing could ensure a more predictable reversal of 357 
over-anticoagulation. In an earlier pilot study of over-anticoagulated patients either 358 
asymptomatic or with minor bleeds (87 episodes in total), we demonstrated that an 359 
individualized vitamin K dosing regimen whereby vitamin K dose was calculated based 360 
upon patient INR on presentation performed better in lowering INR compared to fixed-361 
dose vitamin K (38% v 21% INR within target range at 24 h) (Briz, et al 2010). The 362 
results of the pilot study enabled us to refine the original tailored dosing algorithm. The 363 
latter can estimate vitamin K dose according to index INR, body surface area and target 364 
INR. We have assessed the performance of the new dosing algorithm (measured as the 365 
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proportion of patients returning to within target INR) against that of the fixed-dose 366 
regimen in a randomised parallel design study.  367 
 368 
The present study results demonstrate that the tailored vitamin K dosing regimen is 369 
superior to the fixed-dose regimen; compared to the fixed-dose regimen, the tailored 370 
dose resulted in a greater proportion of patients returning to target INR range, whilst a 371 
smaller proportion remained above target INR range at 24h.  372 
 373 
Using the tailored vitamin K dosing algorithm the patients in the control group who had 374 
received the 1mg vitamin K dose were predicted to require a higher dose of vitamin K 375 
whilst those who had received the 2 mg dose require a slightly lower dose. However, 376 
there was a wide range in the predicted vitamin K doses for each of the fixed doses [for 377 
1mg dose: range 0.1 – 3.0mg; mean difference between predicted and actual dose: 0.7 (-378 
0.9 – 2.0) mg; for 2 mg dose: range 1.0 – 2.7 mg; mean difference between predicted and 379 
actual dose: -0.1 (-1.0 – 0.7) mg] which further suggests that the fixed-dose regimen is 380 
inappropriate for lowering INR for the majority of over-anticoagulated patients.  381 
 382 
Anticoagulation response to warfarin is influenced by environmental, clinical and 383 
genetic factors (Isbister, et al 2001, Sconce, et al 2005) which could also influence 384 
vitamin K dose requirement in over-anticoagulated patients.  We therefore also 385 
determined, retrospectively, whether patient age, sex, co-morbidity and genetic 386 
polymorphisms in the expression of the vitamin K epoxide reductase, the main target 387 
for warfarin (encoded by VKORC1 gene), cytochrome p450 CYP2C9, the enzyme 388 
responsible for the metabolism of S-warfarin (encoded by CYP2C9 gene)(Kamali and 389 
Wynne 2010, Sconce, et al 2005) , and the mono-oxidase enzyme involved in vitamin K1 390 
Page 17 of 32 
 
metabolism (encoded by CYP4F2)(McDonald, et al 2009), affect vitamin K dose and the 391 
extent of INR reversal so that these can be used to further improve the vitamin K dosing 392 
algorithm as appropriate. Overcorrection of INR was more frequent in women than men 393 
(58.6% v 41.4%) although the differences were not statistically significant, likely due to 394 
the small number of patients evaluated. Female sex was found to be independently 395 
associated with overcorrection of INR, despite female subjects on average having 396 
received lower doses of vitamin K than their male counterparts.  Patient factors of age 397 
and body size have previously been reported to influence vitamin K dose requirement 398 
(Hylek, et al 2001, Kelly, et al 2001).  Whilst we found that patient weight and index INR 399 
influenced INR at 24h and hence vitamin K dose requirement, patient age had no effect. 400 
Similar to our previous pilot study, we found that CYP2C9 and VKORC1 polymorphism 401 
made no contribution to vitamin K dose requirement, and neither did polymorphisms in 402 
CYP4F2. However, the present study was not sufficiently powered to detect the 403 
influence of genetics on vitamin K dose requirement. Therefore, it remains possible that 404 
the influence of these genes on vitamin K dose requirement will become apparent in a 405 
purposefully designed study in a larger population of patients.  406 
 407 
There were no incidences of major bleeding requiring intervention, or thromboembolic 408 
events throughout the trial. There were 10 incidences of minor bleeding; patients in the 409 
tailored vitamin K dose group with minor bleeding complications were more likely to be 410 
taking drugs that interact with warfarin (Clopidogrel, Aspirin) or have chronic 411 
comorbidities; factors which are known to increase the risk of bleeding (Tran and 412 
Alderman 2013). 413 
 414 
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In conclusion, the current RCT showed that ‘tailored’ vitamin K dosing regimen was 415 
superior to the fixed-dose regimen, leading to a more accurate reversal of excessive 416 
anticoagulation and a higher percentage of patients returning to within their target INR 417 
range. However, for the true clinical benefit of the tailored vitamin K dosing regimen in 418 
over-anticoagulated patients to be realised, further larger study is required to establish 419 
its clinical utility, as well as its superiority over fixed-dose regimen in terms of its cost-420 
effectiveness, by reducing the burden of management of patients with excessive 421 
anticoagulation through reductions in the number of repeat treatments/follow-ups, and 422 
the potential gains in patient quality of life and treatment safety  in terms of reductions 423 
in the incidences of bleeding and thrombosis.  424 
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Table I:- Patient Characteristics 553 
 Total Control Tailored 
Sample size, n 181 91 90 
Age (years), mean ± SD (range) 71 ± 14 (19-94) 72 ± 14 (19-92) 71 ± 15 (22-94) 
Sex, n (%)  
Female 96 (53) 50 (55) 46 (51) 
Male 85 (47) 41 (45) 44 (49) 
Weight, mean ± SD (range) ⱡ 
75.8 ± 20.7 
(37.0-163.0) 
77.0 ± 19.8 
(43.0-130.9) 
74.6 ± 21.5 
(37.0-163.0) 
BSA, mean ± SD (range) ⱡ 
1.81±0.27 
(1.21-2.81) 
1.82±0.25 
(1.30-2.39) 
1.81±0.29 
(1.21-2.81) 
Indication for anticoagulation, n (%) 
 
 
Atrial fibrillation 81 (44.75) 40 (43.9) 41 (45.6) 
Venous thromboembolism 29 (16) 17 (18.7) 12 (13.3) 
Heart Valve replacement 26 (14.45) 13 (14.3) 13 (14.4) 
Pulmonary embolism 18 (9.9) 9 (9.9) 9 (10) 
Other 27 (14.9) 12 (13.2) 15 (16.7) 
Target INR range, n (%) ◊ 
 
 
2.0-3.0 145 (80.2) 70 (76.9) 75 (83.3) 
2.5-3.5 18 (9.9) 9 (9.9) 9 (10) 
3.0-4.0 18 (9.9) 12 (13.2) 6 (6.7) 
Frequency of concomitant  
medications, n ¥ 
 
No interaction  131 145 
Minor  interaction  19 14 
Moderate interaction  35 38 
Major interaction  17 13 
 ⱡ  Based on data for 175 patients 554 
◊ Based on data for 180 patients 555 
¥ Based on degree of interaction with warfarin556 
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Table II:- INR values on admission, at 24hours and on days 7 and 14 after vitamin 557 
K administration 558 
^ Confidence Interval of the difference between means 559 
* Mann-Whitney test 560 
 Log transformed for data analysis  561 
 Control Tailored 95 % CI^ 
 Mean INR ± SD (range)  
Index INR 7.9 ±1.8 (5.3-17.0) 8.3 ± 2.2 (6.0-21.8) (-0.7002,0.2001)* 
24h 3.3 ± 2.0 (1.2-16.3) 2.5 ± 0.9 (1.1-5.4) (0.1167, 0.3441) 
Day 7 3.2 ± 1.3 (1.4-8.0) 3.0 ± 1.4 (1.3-7.0) (-0.0590, 0.2034) 
Day 14 3.4 ± 1.7 (1.1-9.8) 3.1 ± 1.42 (1.3-8.0) (-0.0638, 0.2290) 
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Table III:- Frequency of INR values below, within and above target range at 24 562 
hours and on days 7 and 14 following vitamin K administration  563 
 564 
 Control Tailored  
 n, (%) p-value 
INR-24h  
Below target range 12 (13.2) 17 (18.9) 0.296 
0.002 Within target range 48 (52.8) 62 (68.9) 0.026 
Above target range 31 (34.0) 11 (12.2)  
Day 7 
Below target range 9 (11.7) 13 (18.3) 
0.480 Within target range 42 (54.5) 38 (53.5) 
Above target range 26 (33.8) 20 (28.2) 
Day 14 
Below target range 6 (8.3) 8 (12.7) 
0.652 Within target range 42 (58.3) 33 (52.4) 
Above target range 24 (33.4) 22 (34.9) 
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Table IV:- Changes in patients’ treatment following study intervention 565 
¢ Based on data for 177 patients 566 
٨ Based on data for 160 patients  567 
 
Total 
patients 
analysed, 
Control Tailored 
P-value 
Warfarin withheld/changed on 
admission, n (%) ¢    
0.567 
Yes 174 87 87 
No 3 2 1 
Warfarin administration 
at 24 h, n (%) ٨    
0.219 
Withheld 29 18 11 
Resumed 131 63 68 
Additional vitamin K 
administration post initial dose 
  
 
At 24h  4 4 0 
48 -96h  3 2 1 
On day 7 4 2 2 
On day 14 5 3 2 
Heparin administration    
At 24h 2 1 1 
After 24 h 20 15 5 
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Table V:- Bleeding and thromboembolic adverse events according to severity and 568 
relation to warfarin treatment 569 
1Unrelated to warfarin 570 
2Possibly related to warfarin 571 
3Probablly related to warfarin 572 
4Definitely related to warfarin  573 
 Bleeding events, n Thromboembolic events, n 
Time of onset Control,  
4 
Tailored regimen, 
6 
Control,  
0 
Tailored,  
1 
2 -7 days post 
intervention  
Bruising (leg)2 
Nose bleed2 
 DVT1 
Specks of blood in phlegm2 
7-23 days post 
intervention 
Haematuria2 Epistaxis, 23,4 
  
Spontaneous bruising 
(eyelid)2 
Bruising (neck)2 
Prolonged bleeding 
after cut3 
Vaginal spotting1 
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Figure Legends 574 
 575 
Figure 1:-Vitamin K dose distribution (actual and predicted dose) per patient group 576 
 577 
Figure 2:- Boxplot showing the median and interquartile range of vitamin K dose 578 
administered according to patient sex in the tailored group 579 
 580 
Figure 3:- Variability in vitamin K dose according to index INR and BSA between the 581 
control and tailored vitamin K dose regimen groups 582 
 583 
Figure 4:- Relationship between the difference in vitamin K dose (predicted - actual 584 
dose), BSA and index INR   585 
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Figure 1 586 
  587 
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Figure 2 588 
  589 
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Figure 3  590 
  591 
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Figure 4 592 
 593 
